
RTW Investments is a life sciences investment and innovation firm headquartered in New York, investing in biotech and medtech across the full lifecycle from company creation to venture capital, alternative financing, and public companies.
73% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (2 deals in the last 12 months vs 9 prior). Average disclosed round size is $147.9M (across 27 rounds with reported amounts).
Portfolio
28
Fund Size
—
Top Stage
Series C
Last 12 Mo
3
Team
Sabera Loughran
Partner Emeritus, Founding COO and CFO
Roderick Wong, MD
Managing Partner, Chief Investment Officer
Dan Glynn
Managing Director, Private Wealth
Lauren Cuje
Managing Director, New Ventures
Matthew Bieret, CPA
Managing Director, Finance
Mike Christman
Managing Director, Operations
Paul Lu, PhD
Managing Director, Head of Corporate Development
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
| PProlium Bioscience, Inc. | Series A | $50M | Mar 2026 |
| Series D | $287M | Jan 2026 | |
| Series B | $120M | Jan 2026 | |
| Growth | $200M | Jun 2025 | |
| Series C | $100M | Jan 2025 | |
| Series A | $200M | Jan 2025 | |
| Series C | $55M | Jan 2025 | |
| Series D | $150M | Dec 2024 | |
| Series A | $140M | Dec 2024 | |
| Series C | $115M | Oct 2024 | |
| Series A | — | Oct 2024 | |
| Series B | $175M | Sep 2024 | |
| Series C | $106.6M | May 2024 | |
| Unknown | — | Oct 2023 | |
| Series B | $118M | Jun 2022 | |
| PPrometheus Biosciences Inc | Unknown | $500M | Jan 2022 |
| Series C | $153M | Jul 2021 | |
| Series C | $153M | Jul 2021 | |
| Series B | $50M | Sep 2020 | |
| Series B | $85M | Jun 2020 | |
| PPrometheus Biosciences Inc | Unknown | $130M | Jan 2020 |
| Series C | $104M | Jun 2019 | |
| Series C | $20M | Jan 2019 | |
| Series B | $63M | Jan 2019 | |
| Growth | $200M | Nov 2018 |
Top Co-Investors
Last updated: 9 September 2026